[心力衰竭中缺铁的诊断和治疗]
Federico Fortuni1, Giuseppe Ciliberti2, Mauro Gori3
1Cardiologia e Fisiopatologia Cardiovascolare, Ospedale "Santa Maria della Misericordia", Università degli Studi, Perugia.
概括
缺铁 ( sideropenia) 影响大约50%的心力衰竭患者,影响生活质量和增加住院风险. 早期诊断和治疗对于改善这些患者的治疗结果至关重要.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
背景情况:
- 心力衰竭 (HF) 患者经常出现缺铁症 (铁症),约占这一群体的50%.
- 在HF中缺铁与功能能力减弱,生活质量降低以及住院和死亡风险增加有关.
研究的目的:
- 审查心力衰竭患者缺铁的患病率,诊断标准和治疗证据.
- 概述HF中 sideropenia的指示,铁配方和管理协议,重点关注减少或轻微减少喷射分数的患者.
主要方法:
- 关于心力衰竭中的铁缺乏研究的文献综述.
- 对 sideropenia 的诊断标准和治疗指南的分析.
- 检查不同HF表型中补充铁的证据.
主要成果:
- 铁缺乏症在HF中非常普遍,与较差的临床结果相关.
- 及时诊断和治疗是必不可少的,特别是在HF中,喷射分数减少或轻微减少.
- 在HF中补充铁的证据与保存的喷射分数仍然有限.
结论:
- 解决缺铁问题对于改善心力衰竭患者的治疗和预后至关重要.
- 需要标准化的诊断和治疗方案,以优化对高风患者 sideropenia 的护理.
- 需要进一步的研究,以澄清铁补充在HF中具有保存的喷射分数的作用.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
302
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
302
Heart Failure Drugs: Diuretics
277
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
277
Heart Failure Drugs: Inotropic Agents
401
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
401
Heart Failure Drugs: β-Blockers
259
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
259
Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Imaging Studies for Cardiovascular System I:Echocardiography
260
Cardiac imaging studies encompass a wide range of noninvasive and minimally invasive techniques designed to visualize the heart's structure and function in detail. One such technique is echocardiography, which uses high-frequency ultrasound waves to produce detailed images of the heart, known as echocardiograms.
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion,...
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion,...
260


